The above results suggested that patients, who were in advanced stages of KIPAN, KIRC, ACC, and PRAD cancers, tended to exhibit higher levels of FAM72B expression, which typically indicated that this gene was associated with tumor progression and may have been indicative of a poorer prognosis. Here, FAM72B is linked to prostate adenocarcinoma.